Clinical trial
Alanosine in Treating Patients With Progressive or Recurrent Malignant Gliomas
NCT00075894 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00075894 |
|---|---|
| Title | Alanosine in Treating Patients With Progressive or Recurrent Malignant Gliomas |
| Official title | A Phase I/II, Open-Label, Non-Randomized, Multicenter, Single Agent Study Of Intravenous SDX-102 For The Treatment Of Patients With MTAP-Deficient High Grade Recurrent Malignant Gliomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | L-alanosine |
| Enrollment | 18 |
| Start date | Mar 1, 2004 |
| First posted | Jan 13, 2004 |
| Last update posted | Jan 13, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: